Search Results - "Blommestein, HM"

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma by Bakker, L J, Thielen, F W, Redekop, W K, Groot, Ca Uyl-de, Blommestein, H M

“…In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized…”
Get full text

EE482 Costs of Proton Therapy During the Start-up Phase Using Time-Driven Activity-Based Costing in the Netherlands by Chen, YH, Klazenga, R, Uyl-De Groot, C, van Vulpen, M, Blommestein, HM

Get full text

POSA165 Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review by Chen, YH, Molenaar, D, Uyl-De Groot, CA, van Vulpen, M, Blommestein, HM

Get full text

POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies by Franken, M, de Groot, S, van Dongen, A, Leeneman, B, Uyl-De Groot, CA, Aarts, MJB, van den Berkmortel, FWPJ, Blank, CU, Boers-Sonderen, MJ, van den Eertwegh, AJM, de Groot, JWB, Haanen, JBAG, Hospers, GAP, Kapiteijn, E, van Not, OJ, Piersma, D, van Rijn, RS, Stevense-den Boer, MAM, Suijkerbuijk, KPM, van der Veldt, AAM, Vreugdenhil, G, Wouters, MWJM, Versteegh, M, Blommestein, HM

Get full text

P71 The Development of a Flexible and Easy to Tailor Disease Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma by Combining Trial and Real-World Data by de Groot, S, Blommestein, HM, Leeneman, B, Uyl-De, Groot CA, Haanen, JBAG, Suijkerbuijk, KPM, Aarts, M.J.B., van den Berkmortel, FWPJ, Blank, CU, Boers-Sonderen, MJ, van den Eertwegh, AJM, de Groot, JWB, Hospers, GAP, Kapiteijn, E, de Meza, MM, Piersma, D, van Rijn, RS, Stevense-den Boer, MAM, van der Veldt, AAM, Vreugdenhil, G, Wouters, MWJM, Franken, M, van Baal, PHM

Get full text

POSC366 Validity of the EQ-5D-3L and EQ-5D-5L in Advanced Melanoma by Franken, M, van Dongen, A, Leeneman, B, Uyl-De Groot, CA, Aarts, MJB, van den Berkmortel, FWPJ, Blank, CU, Boers-Sonderen, MJ, van den Eertwegh, AJM, de Groot, JWB, Haanen, JBAG, Hospers, GAP, Kapiteijn, E, de Meza, MM, Piersma, D, van Rijn, RS, Stevense-den Boer, MAM, Suijkerbuijk, KPM, van der Veldt, AAM, Vreugdenhil, G, Wouters, MWJM, Blommestein, HM, Versteegh, M

Get full text

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients' Needs? by Jongbloed, Elisabeth M, Blommestein, Hedwig M, van Schoubroeck, Hannah M, Martens, John W M, Wilting, Saskia M, Uyl-de Groot, Carin A, Jager, Agnes

“…The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2- early breast cancer (EBC)…”
Get full text

PCN235 - Real-World Evidence on Healthcare Resource use and Associated Cost With Multiple Myeloma in The Netherlands by Blommestein, HM, Verelst, SG, Zagorska, A, Stevanovic, J, Engstrom, A, Sonneveld, P, Huijgens, PC, Lefevre, C, Uyl-De Groot, CA

Get full text

Real-World Evidence on Healthcare Resource use and Associated Cost With Multiple Myeloma in The Netherlands by Blommestein, HM, Verelst, SG, Zagorska, A, Stevanovic, J, Engstrom, A, Sonneveld, P, Huijgens, PC, Lefevre, C, Uyl-De Groot, CA

Get full text

PSY9 - Second-Line Treatment for Steroid-Refractory Graft-Versus-Host Disease with Mesenchymal Stromal Cells. A Conceptual Disease Model by Thielen, F, Blommestein, HM, Oosten, L, Fibbe, W, Le Blanc, K, Locatelli, F, Sánchez-Guijo, F, Calkoen, F, Lankester, A, Algeri, M, Redondo-Guijo, A, Uyl-de Groot, CA

Get full text

Long-Term Disease Outcomes in Symptomatic Multiple Myeloma Patients: A Retrospective Analysis of the Pharos Registry by Verelst, SG, Blommestein, HM, De Groot, S, Gonzalez-McQuire, S, DeCosta, L, de Raad, J, Sonneveld, P, Uyl-de Groot, CA

Get full text

PCN204 - Long-Term Disease Outcomes in Symptomatic Multiple Myeloma Patients: A Retrospective Analysis of the Pharos Registry by Verelst, SG, Blommestein, HM, De Groot, S, Gonzalez-McQuire, S, DeCosta, L, de Raad, J, Sonneveld, P, Uyl-de Groot, CA

Get full text

Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model by Thielen, Frederick W., Blommestein, Hedwig M., Oosten, Liesbeth E.M., Calkoen, Friso G., Lankester, Arjan C., Zwaginga, Jaap J., Le Blanc, Katarina, Redondo, Alba, Sánchez‐Guijo, Fermin, Algeri, Mattia, Locatelli, Franco, Fibbe, Wim E., Uyl‐de Groot, Carin A.

“…Objective No standard second‐line treatment exists for acute graft‐versus‐host disease steroid‐refractory (SR‐aGvHD), and long‐term outcomes remain poor…”
Get full text

Second-Line Treatment for Steroid-Refractory Graft-Versus-Host Disease with Mesenchymal Stromal Cells. A Conceptual Disease Model by Thielen, F, Blommestein, HM, Oosten, L, Fibbe, W, Le Blanc, K, Locatelli, F, Sánchez-Guijo, F, Calkoen, F, Lankester, A, Algeri, M, Redondo-Guijo, A, Uyl-de Groot, CA

“…OBJECTIVES: Success rates of allogenic haematopoietic stem cell transplantation are tarnished by high incidences of acute graft-versus-host disease (aGvHD)…”
Get full text